CRIS Current Research Information System

MARCHETTI, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.035
NA - Nord America 811
EU - Europa 709
SA - Sud America 165
AF - Africa 92
OC - Oceania 1
Totale 3.813
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 791
SG - Singapore 776
CN - Cina 630
IT - Italia 236
HK - Hong Kong 191
KR - Corea 160
VN - Vietnam 147
BR - Brasile 126
NL - Olanda 114
SE - Svezia 66
DE - Germania 64
IN - India 59
CI - Costa d'Avorio 47
IE - Irlanda 34
SC - Seychelles 34
FI - Finlandia 29
RU - Federazione Russa 27
GB - Regno Unito 25
AT - Austria 23
FR - Francia 23
CH - Svizzera 22
JP - Giappone 19
JO - Giordania 16
AR - Argentina 15
BG - Bulgaria 13
ID - Indonesia 13
PL - Polonia 13
CA - Canada 12
CL - Cile 11
EC - Ecuador 5
BD - Bangladesh 4
LT - Lituania 4
MX - Messico 4
PK - Pakistan 4
ZA - Sudafrica 4
CO - Colombia 3
ES - Italia 3
PT - Portogallo 3
TG - Togo 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
DO - Repubblica Dominicana 2
KZ - Kazakistan 2
TR - Turchia 2
TW - Taiwan 2
UY - Uruguay 2
VE - Venezuela 2
AU - Australia 1
BA - Bosnia-Erzegovina 1
BE - Belgio 1
BH - Bahrain 1
BY - Bielorussia 1
CY - Cipro 1
EE - Estonia 1
GR - Grecia 1
HN - Honduras 1
IL - Israele 1
IQ - Iraq 1
IR - Iran 1
KE - Kenya 1
KG - Kirghizistan 1
LB - Libano 1
LV - Lettonia 1
MA - Marocco 1
ML - Mali 1
MZ - Mozambico 1
NI - Nicaragua 1
PE - Perù 1
RS - Serbia 1
TH - Thailandia 1
UA - Ucraina 1
Totale 3.813
Salva come PNG Salva come JPEG
Città #
Singapore 542
Hefei 281
Hong Kong 188
Ashburn 173
Seoul 159
Santa Clara 86
Beijing 73
Bologna 59
Boardman 50
Abidjan 47
Hanoi 42
Ho Chi Minh City 39
Chandler 36
Los Angeles 34
Dublin 33
Dallas 27
Bengaluru 26
Redondo Beach 23
Milan 20
Bern 19
Guangzhou 19
Helsinki 19
Tokyo 18
Castel Maggiore 17
São Paulo 17
Amman 16
Vienna 16
Amsterdam 14
New York 14
Munich 13
Sofia 13
Tongling 12
Turin 12
Buffalo 11
Falkenstein 11
Nuremberg 10
Warsaw 10
Rome 9
Shanghai 9
Biên Hòa 8
Fairfield 8
Princeton 8
Southend 8
Hyderabad 7
Lappeenranta 7
Boston 6
Frankfurt am Main 6
Jakarta 6
Nanjing 6
Chicago 5
Haiphong 5
Houston 5
London 5
Montreal 5
Moscow 5
Redmond 5
San Polo di Torrile 5
Seattle 5
Stockholm 5
Zhengzhou 5
Atlanta 4
Bari 4
Berlin 4
Boydton 4
Brooklyn 4
Changsha 4
Da Nang 4
Florence 4
Genoa 4
Rimini 4
Toronto 4
Xi'an 4
Belo Horizonte 3
Bexley 3
Bühl 3
Cambridge 3
Castel Mella 3
Charlotte 3
Columbus 3
Enschede 3
Lomé 3
Maipú 3
Mexico City 3
Modena 3
Mumbai 3
Ninh Bình 3
Orem 3
Paris 3
Phoenix 3
Phú Thọ 3
Rio de Janeiro 3
San Diego 3
San Francisco 3
Santiago 3
Shijiazhuang 3
Sorocaba 3
São Bernardo do Campo 3
Telgate 3
Terno d'Isola 3
Turku 3
Totale 2.474
Salva come PNG Salva come JPEG
Nome #
Insights into the impact of chromosome 3p mutations in advanced renal cell carcinoma treated with immune-based combinations or targeted therapy: A single-center experience 142
Bone targeting agents in patients with metastatic prostate cancer: State of the art 138
Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw 129
A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy 129
A prospective study on the early evaluation of response to androgen receptor-targeted agents with 11C-Choline, 68Ga-PSMA, and 18F-FACBC PET in metastatic castration-resistant prostate cancer: a single-center experience 127
Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study 125
Prognostic Factors of Survival for High-Grade Neuroendocrine Neoplasia of the Bladder: A SEER Database Analysis 125
Tumor growth rate to assess therapy response to immune-based combinations for metastatic renal cell carcinoma 124
The value of molecular features in predicting efficacy of immuno-combinations in kidney cancer: just a drop in the ocean? 123
Dual-energy spectral CT in renal cell carcinoma: dawn of a brand-new era? 120
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study 119
Hypertransaminasemia in metastatic renal cell carcinoma patients receiving immune-based combinations: a meta-analysis 113
Development and validation of a new tool to estimate early mortality in patients with advanced cancer treated with immunotherapy 111
State of the art of adjuvant immunotherapy in urothelial cancer: New developments and upcoming changes 107
Impact of HER2 assessment by CISH in urothelial carcinoma: A retrospective single-center experience 105
Novel Immune Checkpoint Inhibitor Targets in Advanced or Metastatic Renal Cell Carcinoma: State of the Art and Future Perspectives 101
Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: A meta-analysis 99
Chromosome 3p gene alterations as biomarkers for immunocombinations in metastatic renal cell carcinoma: A hypothesis-generating analysis 89
Quality of life assessment in renal cell carcinoma Phase II and III clinical trials published between 2010 and 2020: A systematic review 87
An update on safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma 81
Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials 77
Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials 72
Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma 71
Implications of TERT promoter mutations and telomerase activity in solid tumors with a focus on genitourinary cancers 65
The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study 64
Exploring the association between metastatic sites and androgen receptor splice variant 7 (AR-V7) in castration-resistant prostate cancer patients: A meta-analysis of prospective clinical trials 62
Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study 58
Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1) 58
18F-Fluorodeoxyglucose Uptake in PDGFRA-Mutant Gastrointestinal Stromal Tumors 57
An insight on novel molecular pathways in metastatic prostate cancer: A focus on ddr, msi and akt 57
How Do Molecular Classifications Affect the Neoadjuvant Treatment of Muscle-Invasive Urothelial Carcinoma? 56
Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy 56
Adapting to hormone-therapy resistance for adopting the right therapeutic strategy in advanced prostate cancer 54
Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis 52
TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab 51
Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancer 50
What is the risk of hepatotoxicity induced by immune-checkpoint inhibitors and how can we avoid it? 49
Do we need alternative PD-1 inhibitors for the treatment of renal cell carcinoma? 46
Current androgen receptor antagonists under investigation for resistant prostate cancer: progress and challenges 45
Current androgen receptor antagonists under investigation for resistant prostate cancer 44
Clinical outcomes and prognostic factors in patients with penile carcinoma: a sub-analysis from Meet-URO 23 (I-RARE) registry study 44
Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis 43
Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma 38
Prostate cancer and novel pharmacological treatment options - what's new for 2022? 37
The Prognostic Role of 68GA-PSMA-PET/CT in Metastatic Hormone-Sensitive Prostate Cancer: A Preliminary Analysis 37
Immunohistochemical expression of EZH2 in germ cell tumors of the testis: New insights into the genesis and epigenetic reprogramming of these fascinating tumors 36
Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials 34
An up-to-date evaluation of cabozantinib for the treatment of renal cell carcinoma 32
Risk of toxicity with immunotherapy-tyrosine kinase inhibitors for metastatic renal cell carcinoma: a meta-analysis of randomized controlled trials 32
Re: Atezolizumab Plus Cabozantinib Versus Cabozantinib Monotherapy for Patients with Renal Cell Carcinoma After Progression with Previous Immune Checkpoint Inhibitor Treatment (CONTACT-03): A Multicentre, Randomised, Open-label, Phase 3 Trial 28
Determinants of treatment for first-line immune-based combinations in metastatic renal cell carcinoma: A critical overview of recent evidence 27
The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: The MOUSEION-01 study 24
Immunohistochemical expression of Nectin-4 and potential implications for enfortumab vedotin therapy in germ cell tumors of the testis: a preliminary study 23
Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study 22
Pathological and Clinical Implications of Tumor Microenvironment Evaluated With Multiplex Immunohistochemistry in Testicular Embryonal Carcinoma 16
Re: First-line Therapy for Advanced Non-Clear Cell Renal Cell Carcinoma. A Systematic Review and Meta-analysis 13
Totale 3.924
Salva come PNG Salva come JPEG
Categoria #
all - tutte 12.468
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.468
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202112 0 0 0 0 0 0 0 0 0 7 0 5
2021/202282 0 0 1 3 2 1 6 20 5 3 29 12
2022/2023341 4 14 7 15 34 32 20 17 90 9 55 44
2023/2024218 19 36 20 14 18 27 6 16 15 12 21 14
2024/20251.409 61 137 96 89 143 58 78 55 34 122 211 325
2025/20261.862 347 445 349 311 347 63 0 0 0 0 0 0
Totale 3.924